Succinyl-farnesyl-cysteine compounds for treating bacterial resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to bacterial colonization of mammalian epithelium, such as skin infections, face challenges due to emerging bacterial resistance to antibiotics, necessitating innovative and cost-effective methods for effective treatment, prevention, and management.
Innovation Solution
Development of novel isoprenyl compounds structurally related to N-acetyl-5-farnesyl-L-cysteine (AFC) with a succinyl moiety, known as succinyl-farnesyl-cysteines (SFCs), which modulate the G-protein signaling cascade, exhibiting both anti-inflammatory and antibacterial activities, capable of inhibiting edema, erythema, and dermal neutrophil infiltration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional anti-bacterial agents are used to treat epithelial conditions caused by bacterial colonization, then effective treatment is achieved, but bacterial resistance emerges
Solution Approach 1:
The patent modifies the chemical structure of N-acetyl-farnesyl-cysteine by replacing the acetyl group with a succinyl group to create N-succinyl-farnesyl-cysteine. This parameter change in the molecular structure produces a compound with enhanced anti-inflammatory and antibacterial activity that overcomes bacterial resistance to traditional antibiotics
Solution Approach 2:
The invention creates a composite therapeutic agent that combines both anti-inflammatory and antibacterial properties in a single compound. The N-succinyl-farnesyl-cysteine molecule integrates multiple functional capabilities, allowing simultaneous treatment of inflammation and bacterial infection while preventing resistance development
2Object-affected harmful factors
If traditional anti-inflammatory drugs (corticosteroids and NSAIDs) are used to treat inflammation, then inflammation is reduced, but multiple side effects occur
Solution Approach 1:
The patent modifies the chemical structure of N-acetyl-farnesyl-cysteine by replacing the acetyl group with a succinyl group to create N-succinyl-farnesyl-cysteine. This parameter change in the molecular structure produces a compound with enhanced anti-inflammatory and antibacterial activity that overcomes bacterial resistance to traditional antibiotics
Solution Approach 2:
The invention creates a novel compound structure that copies and enhances the beneficial effects of natural cysteinyl compounds while avoiding the harmful side effects of synthetic anti-inflammatory drugs. The succinyl-farnesyl-cysteine structure is designed to interact with inflammatory pathways more selectively and safely
Data Source
AI summary
Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease).